Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
TVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.12 - $25.29
Previous CloseN/A
Volume140.04K
Average Volume (3M)1.84M
Market Cap
$1.76B
Enterprise Value$1.21B
Total Cash (Recent Filing)$43.25M
Total Debt (Recent Filing)$404.02M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
May 01, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding88,739,820
10 Day Avg. Volume1,835,332
30 Day Avg. Volume1,843,075
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.54
Price to Cash Flow (P/CF)-12.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.20
Enterprise Value/Ebitda-4.56
Forecast
1Y Price Target
$34.62Price Target Upside75.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
EarningsFilspari achieved a significant 40% quarter-over-quarter sales growth, showcasing strong demand for the product.
Regulatory ProgressThe FDA has accepted Travere’s sNDA to reduce liver function test monitoring frequency, a critical step to streamline commercial adoption.
Bears Say
GuidanceThe company did not provide FY25 guidance for Filspari, which may disappoint some.
---
Ownership Overview
1.49% Insiders
21.14% Mutual Funds
44.12% Other Institutional Investors
17.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $5.12 and its highest was $25.29 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $1.76B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 56 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Feb 20, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.562 by -$0.168.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 88,739,820 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.562. Following the earnings report the stock price went down -6.785%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
---
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.62 (75.74% Upside)
$34.62 (75.74% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 4.2%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
151.58%
12-Months-Change
Fundamentals
Return on Equity
-246.75%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics is focused on developing therapies for rare kidney and metabolic disorders. The biopharmaceutical company's products include FILSPARI (sparsentan), and Thiola and Thiola EC (tiopronin tablets).
---
TVTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with significant achievements such as FDA approval and sales growth of FILSPARI, expansion plans into FSGS indication, and strong financial performance. However, challenges remain with declining sales of Thiola due to generic competition and a substantial net loss for the year.Read More>---
TVTX Stock 12 Month Forecast
Average Price Target
$34.62
▲(75.74% Upside)
Technical Analysis
Amgen
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering TVTX
1 Year
1 Year Success Rate
17/27 ratings generated profit
1 Year Average Return
+21.85%
reiterated a buy rating 13 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +21.85% per trade.
---